Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2011-09-13 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
FDA Approval Of New Dual-Scored 150mg Doryx Tablet 2 pages 491.8KB
Capital/Financing Update Classification · 85% confidence The document is a press release announcing FDA approval of a new dual-scored 150mg Doryx tablet by Mayne Pharma. It discusses product details, regulatory approval, patent status, and marketing plans. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (3467 characters) and serves as a corporate announcement about a product approval rather than a financial or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is an announcement related to product approval and marketing, which is best categorized under Capital/Financing Update (CAP) as it relates to product lifecycle management and market strategy, or alternatively Regulatory Filings (RNS) as a general announcement. However, since it is specifically about FDA approval and product launch plans, CAP is the closest relevant category.
2011-09-13 English
Annual Report to shareholders 74 pages 3.3MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2011' and contains detailed sections typical of an annual report, including business overview, company highlights, chairman's letter, CEO review, financial summary, directors' report, remuneration report, auditor's independence declaration, corporate governance statement, and consolidated financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and operational information for the fiscal year 2011, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K).
2011-09-12 English
Notice of Annual General Meeting/Proxy Form 8 pages 727.9KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting 2011' and includes detailed information about the upcoming AGM, including date, time, location, business to be conducted, resolutions to be voted on (such as re-election of directors and adoption of the Remuneration Report), proxy voting instructions, and explanatory notes. It does not contain the actual financial statements or reports but rather notifies shareholders of the meeting and the agenda. The document is lengthy (15,000 characters) but is clearly a notice and explanatory material for the AGM, not the Annual Report or Remuneration Report itself. Therefore, it fits the definition of AGM Information (AGM-R).
2011-09-12 English
Preliminary Final Report 19 pages 593.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Mayne Pharma Group Preliminary Final Report and accompanying announcement' and references the Appendix 4E Preliminary Final Report for the year ended 30 June 2011. It includes detailed financial results such as revenue, EBITDA, net profit after tax, segment performance, cash flow, and outlook commentary. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. Appendix 4E is a regulatory filing used in Australia for preliminary final reports, which are comprehensive annual financial reports but not the full annual report (10-K equivalent). The document contains detailed financial data and analysis for the full fiscal year, consistent with a comprehensive annual financial report. Therefore, the document is best classified as an Interim / Quarterly Report (IR) because Appendix 4E preliminary final reports are considered interim reports under ASX rules, providing detailed financial results for the year but not the full annual report. It is not a simple announcement or a certification, and it contains substantive financial data and analysis. FY 2011
2011-08-30 English
FY11 Financial Results Presentation 17 pages 418.2KB
Investor Presentation Classification · 95% confidence The document is titled 'FY11 Results Presentation' and dated 31 August 2011, indicating it is a presentation of the full fiscal year 2011 results. It contains detailed financial data including revenue, EBITDA, NPAT, EPS, balance sheet figures, cash flow, and segment sales breakdown. It also discusses business strategy, regulatory updates, product development, and milestones. The presence of slides and summary points is typical of an investor presentation rather than a formal annual report or earnings release. The document length is over 10,000 characters, indicating it is a full presentation rather than a brief announcement. There is no indication that this is a transcript, audit report, or regulatory filing. Therefore, the document best fits the category of an Investor Presentation (IP).
2011-08-30 English
Appendix 3B 7 pages 302.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically employee options, and an application for quotation of additional securities on the ASX (Australian Securities Exchange). It details the class of securities, number issued, exercise price, vesting and expiry dates, and other terms related to the securities issuance. The document is regulatory in nature, focused on capital raising and securities issuance, not a financial report or management discussion. It fits the category of Capital/Financing Update (CAP) as it announces new share options issued under an employee plan and applies for quotation of these securities.
2011-07-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.